

UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,305)

PATENT

04/24/00
13808 U.S. PT

In the Application of:

Briscoe et al.


Serial No. 09/466,325

Filing Date 12-17-99

Group Art Unit: 1743

Examiner: To be assigned

For: Microchip PCR Device and Array)



TRANSMITTAL LETTER

Asst. Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:

- a) Information Disclosure Statement;
- b) PTO Form 1449; and cited references
- c) Return postcard

2. With respect to fees:

- a) No fees are required
- b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage Express Mail in an envelope addressed to the Asst. Commissioner for Patents, Washington, D.C. 20231 on April 24, 2000.

Respectfully submitted,

Date: 24 April 2000

Kevin E. Noonan, Ph.D.
Registration No. 35,303

#4

UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,305)

PATENT

In the Application of:

Briscoe et al.

Serial No. 09/466,325

Filing Date 12-17-99

For: Microchip PCR Device and Array

Group Art Unit:1743

Examiner: To be assigned

RECEIVED
MAY -3 2000
TC 1700 MAIL ROOM

INFORMATION DISCLOSURE STATEMENT

Asst. Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Sections 1.97 - 1.99, the Applicants wish to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

It is requested that the references be given careful consideration and that they be cited of record in the present application so that they will appear on the face of the patent issuing from the present application. Return of an initialed PTO-1449 indicating the Examiner's consideration of the references is requested.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within

the meaning of 35 U.S.C. Sections 102 or 103. This Information Disclosure Statement shall not be construed as an admission that the statement or cited references are, or are considered to be, material to patentability. 37 C.F.R. Section 1.97(h).

U.S. Patents

U.S. 5,498,392

U.S. 5,587,128

U.S. 5,589,136

Other Documents

Wilding et al., 1994, Clin. Chem. 40:1815-18

Shoffer et al., 1996, Nucleic Acids Res. 24:375-79

Cheng et al., 1996, Nucleic Acids Res. 24:380-85

Woodley et al., 1996, Anal. Chem. 68:4081-86

Northrup et al., 1998, Anal. Chem. 70:918-22

Ibrahim et al., 1998, Anal. Chem. 70:2013-17


Belgrader et al., 1998, Clin. Chem 44:2191-94

Date:

4/24/00

By:

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff



Kevin E. Noonan
Reg. No. 35,303